ANTIMICROBIAL INNOVATION ALLIANCE

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2013–2025

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	4	1
2020	—	1	1
2019	—	4	1
2018	—	4	1
2017	—	4	1
2016	—	4	1
2015	—	5	1
2014	—	4	1
2013	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
THE MCMANUS GROUP	—	29
FORBES-TATE	—	20

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	38
SENATE	38
Health & Human Services, Dept of (HHS)	4
Office of Management & Budget (OMB)	3
Food & Drug Administration (FDA)	2
Executive Office of the President (EOP)	1
Office of Personnel Management (OPM)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	41
Medicare/Medicaid	Medicare/Medicaid	13
Budget/Appropriations	Budget/Appropriations	5

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 3932117th Congress

PASTEUR Act of 2021

2022 · fourth_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the H.R.3932/S.2076 - PASTEUR Act of 2021

Client expense: — · Firm income: —

Matched citations: H.R.3932

S. 2076117th Congress

PASTEUR Act of 2021

2022 · fourth_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the H.R.3932/S.2076 - PASTEUR Act of 2021

Client expense: — · Firm income: —

Matched citations: S.2076

H.R. 3932117th Congress

PASTEUR Act of 2021

2022 · third_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the H.R.3932/S.2076 - PASTEUR Act of 2021.

Client expense: — · Firm income: —

Matched citations: H.R.3932

S. 2076117th Congress

PASTEUR Act of 2021

2022 · third_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the H.R.3932/S.2076 - PASTEUR Act of 2021.

Client expense: — · Firm income: —

Matched citations: S.2076

Show 21 more cited filings

H.R. 3932117th Congress

PASTEUR Act of 2021

2022 · second_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the H.R.3932/S.2076 - PASTEUR Act of 2021.

Client expense: — · Firm income: —

Matched citations: H.R.3932

S. 2076117th Congress

PASTEUR Act of 2021

2022 · second_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the H.R.3932/S.2076 - PASTEUR Act of 2021.

Client expense: — · Firm income: —

Matched citations: S.2076

H.R. 3932117th Congress

PASTEUR Act of 2021

2022 · first_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the H.R.3932/S.2076 - PASTEUR Act of 2021

Client expense: — · Firm income: —

Matched citations: H.R.3932

S. 2076117th Congress

PASTEUR Act of 2021

2022 · first_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the H.R.3932/S.2076 - PASTEUR Act of 2021

Client expense: — · Firm income: —

Matched citations: S.2076

S. 4760116th Congress

The PASTEUR Act

2021 · fourth_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the S.4760 (116th Congress) - The PASTEUR Act.

Client expense: — · Firm income: —

Matched citations: S.4760

S. 4760116th Congress

The PASTEUR Act

2021 · third_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the S.4760 (116th Congress) - The PASTEUR Act.

Client expense: — · Firm income: —

Matched citations: S.4760

H.R. 6294115th Congress

REVAMP Act

2018 · fourth_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Support for H.R. 6294 - REVAMP Act.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6294

H.R. 6294115th Congress

REVAMP Act

2018 · third_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Support for H.R. 6294 - REVAMP Act.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6294

H.R. 6294115th Congress

REVAMP Act

2018 · second_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Support for H.R. 6294 - REVAMP Act. Support for antimicrobial incentives to be included in S. 2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6294

S. 2852115th Congress

Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018

2018 · second_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Support for H.R. 6294 - REVAMP Act. Support for antimicrobial incentives to be included in S. 2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018.

Client expense: — · Firm income: $50,000

Matched citations: S. 2852

H.R. 2430115th Congress

FDA Reauthorization Act of 2017

2017 · third_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017.

Client expense: — · Firm income: $120,000

Matched citations: H.R. 2430

S. 934115th Congress

FDA Reauthorization Act of 2017

2017 · third_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017.

Client expense: — · Firm income: $120,000

Matched citations: S. 934

H.R. 2430115th Congress

FDA Reauthorization Act of 2017

2017 · second_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2430

S. 934115th Congress

FDA Reauthorization Act of 2017

2017 · second_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017.

Client expense: — · Firm income: $60,000

Matched citations: S. 934

H.R. 2029114th Congress

Consolidated Appropriations Act, 2016

2016 · fourth_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

H.R.2029 - Consolidated Appropriations Act, 2016.

Client expense: — · Firm income: $80,000

Matched citations: H.R.2029

H.R. 512114th Congress

DISARM Act of 2015

2016 · fourth_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Development of policies to advance the antimicrobial research and development environment; including advancing new market incentives. Support of H.R. 512 - DISARM Act of 2015 language in H.R. 6 - The 21st Century Cures Act. Antibiotic policy regarding Innovation for Healthier Americans Report.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 512

H.R. 6114th Congress

21st Century Cures Act

2016 · fourth_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Development of policies to advance the antimicrobial research and development environment; including advancing new market incentives. Support of H.R. 512 - DISARM Act of 2015 language in H.R. 6 - The 21st Century Cures Act. Antibiotic policy regarding Innovation for Healthier Americans Report.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 6

H.R. 2029114th Congress

Consolidated Appropriations Act, 2016

2016 · third_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

H.R.2029 - Consolidated Appropriations Act, 2016.

Client expense: — · Firm income: $80,000

Matched citations: H.R.2029

H.R. 512114th Congress

DISARM Act of 2015

2016 · third_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Development of policies to advance the antimicrobial research and development environment; including advancing new market incentives. Support of H.R. 512 - DISARM Act of 2015 language in H.R. 6 - The 21st Century Cures Act. Antibiotic policy regarding Innovation for Healthier Americans Report.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 512

H.R. 6114th Congress

21st Century Cures Act

2016 · third_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Development of policies to advance the antimicrobial research and development environment; including advancing new market incentives. Support of H.R. 512 - DISARM Act of 2015 language in H.R. 6 - The 21st Century Cures Act. Antibiotic policy regarding Innovation for Healthier Americans Report.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 6

H.R. 2029114th Congress

Consolidated Appropriations Act, 2016

2016 · second_quarter · Firm: THE MCMANUS GROUP

Open original LDA filing ↗

Cited source text and reported amounts

H.R.2029 - Consolidated Appropriations Act, 2016.

Client expense: — · Firm income: $80,000

Matched citations: H.R.2029

Source: Senate LDA

ANTIMICROBIAL INNOVATION ALLIANCE — Lobbying Disclosure | Poliscope